Holen Sie sich die Stockscreener-App
179.89
2.11%
3.71
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Is Biogen (BIIB) Pricing Reflect Its Cash Flow Value After Mixed Long Term Returns - simplywall.st
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for - Finviz
Oppenheimer Adjusts Biogen Price Target to $225 From $205, Maintains Outperform Rating - marketscreener.com
Oppenheimer Raises Price Target for Biogen (BIIB) to $225 | BIIB Stock News - GuruFocus
Biogen Must Face Union Class Action Over Multiple Sclerosis Drug - Bloomberg Law News
Biogen's Autoimmune Disease Candidate Gets FDA's Breakthrough Status - Finviz
Biogen Can't Escape Amended Antitrust Suit Over MS Drug - Law360
FDA ‘Breakthrough’ status for Biogen’s litifilimab - The Pharma Letter
FDA grants breakthrough therapy designation to Biogen’s litifilimab - Investing.com
Biogen (BIIB) Achieves Breakthrough Therapy Status for CLE Treat - GuruFocus
Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options - Biogen
FDA fast-tracks Biogen lupus drug for scarring skin disease with no targeted treatment - Stock Titan
US Market Recap: Can Biogen Inc. lead its sector in growthIndex Update & Weekly Setup with ROI Potential - mfd.ru
Incredible Growth of Recombinant Dna Technology Market - openPR.com
Expert Outlook: Biogen Through The Eyes Of 11 Analysts - Benzinga
Citigroup Maintains Neutral Rating on Biogen (BIIB), Raises Pric - GuruFocus
Tau Inhibitor Market Is Going to Boom |• Eli Lilly and Company • Biogen Inc. - openPR.com
Eisai Submits Marketing Authorisation Variation to EMA for Intraous Maintenance Dosing Every Four Weeks with Leqembi - marketscreener.com
Will FDA’s Priority Review of At‑Home LEQEMBI IQLIK Dosing Change Biogen’s (BIIB) Narrative - Yahoo Finance
Biogen Surpasses Expectations with Robust Quarterly Performance and Regulatory Milestone - AD HOC NEWS
Biogen (BIIB) Valuation Check As Shares Trade Below Analyst Targets And Long Term Returns Stay Under Pressure - Yahoo Finance
AEGON ASSET MANAGEMENT UK Plc Takes Position in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. (BIIB) Stock Analysis: A Closer Look At Its 11.98% Potential Upside - DirectorsTalk Interviews
FDA Reviews Biogen's (BIIB) Alzheimer's Drug Lecanemab-irmb Appl - GuruFocus
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review - ACN Newswire
FDA Accepts LEQEMBI IQLIK (Lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Priority Review - 富途牛牛
Eisai and Biogen Launch LEQEMBI IQLIK, FDA Review Set for May 2026 - Intellectia AI
Eisai and Biogen Announce FDA Review of LEQEMBI IQLIK, a First-of-Its-Kind At-Home Injection Treatment for Alzheimer's Disease - Quiver Quantitative
FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease under Priority Review - Biogen
FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review - StreetInsider
FDA grants priority review to weekly at-home Alzheimer's injections - Stock Titan
Sector Gamma AS Has $10.57 Million Holdings in Biogen Inc. $BIIB - MarketBeat
AMF Tjanstepension AB Sells 25,636 Shares of Biogen Inc. $BIIB - MarketBeat
Assessing Biogen (BIIB) Valuation After New EU Approval For High Dose Spinraza - simplywall.st
Looking Into Biogen Inc's Recent Short Interest - Sahm
Biogen (NASDAQ:BIIB) Stock Price Expected to Rise, Wedbush Analyst Says - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Teleflex (TFX) and Biogen (BIIB) - The Globe and Mail
High Dose SPINRAZA EU Approval Might Change The Case For Investing In Biogen (BIIB) - simplywall.st
Postpartum Depression Drugs Market Size to Surpass USD 1.97 Billion by 2033, Due to Increasing Awareness & Fast Development of Pharmaceuticals – SNS Insider - GlobeNewswire Inc.
Priya Singhal’s Blueprint For Biogen’s Next Act - Citeline News & Insights
Spinocerebellar Ataxias Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma - Barchart.com
Biogen Inc (BIIB) Shares Up 3.16% on Jan 21 - GuruFocus
Gene Therapy Market Innovations and Key Players: Biogen, - openPR.com
Rakuten Investment Management Inc. Buys Shares of 198,572 Biogen Inc. $BIIB - MarketBeat
Patient Capital Management LLC Has $55.56 Million Stake in Biogen Inc. $BIIB - MarketBeat
Biogen’s High Dose Spinraza Win Extends SMA Treatment Options In EU - simplywall.st
Massachusetts Financial Services Co. MA Purchases 11,685 Shares of Biogen Inc. $BIIB - MarketBeat
Biogen’s Alisha Alaimo On The Company’s Next Big Commercial Build - Citeline News & Insights
3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026 - Yahoo Finance
40 Under 40: Kevin Conway, Biogen - Medical Marketing and Media
(BIIB) and the Role of Price-Sensitive Allocations - Stock Traders Daily
FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease - ADVFN
4 Next-Gen Candidates That Could Form the Future of Alzheimer’s Treatment - BioSpace
Zacks Research Has Positive Estimate for Biogen Q4 Earnings - MarketBeat
The Truth About Biogen Inc: Is Wall Street’s New Alzheimer’s Obsession Worth Your Money? - AD HOC NEWS
SG Americas Securities LLC Trims Holdings in Biogen Inc. $BIIB - MarketBeat
Would You Still Hold Biogen Stock If It Fell Another 30%? - Trefis
Strong Cash Yield: Is Biogen Stock A Buy? - Trefis
Biogen Inc.: Can an Aging Neurology Giant Reinvent Itself Around Alzheimer’s? - AD HOC NEWS
Biogen (BIIB) Valuation Check As High Dose Spinraza Wins Key European Approval - simplywall.st
June 2027 Options Now Available For Biogen (BIIB) - Nasdaq
Biogen Inc. (NASDAQ:BIIB) Short Interest Update - MarketBeat
Nordea Investment Management AB Has $18.20 Million Stock Position in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. stock underperforms Wednesday when compared to competitors - MSN
1.82%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):